{"schema_version":"secwatch.filing_event.v1","accession":"0001619856-22-000029","form_type":"8-K","ticker":"CRBU","cik":"0001619856","company_name":"Caribou Biosciences, Inc.","filed_at":"2022-11-29T23:59:59+00:00","discovered_at":"2026-05-14T18:03:51.461210+00:00","generated_at":"2026-06-21T12:17:39.619368+00:00","sec_items":["7.01","8.01","9.01"],"event_type":"regulatory","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Caribou Bio receives RMAT and Fast Track designations from FDA for CB-010 CAR-T therapy","bullets":["FDA grants RMAT for relapsed/refractory large B cell lymphoma (LBCL) and Fast Track for r/r B-NHL for CB-010.","CB-010 is first allogeneic anti-CD19 CAR-T with PD-1 knockout in clinic.","In ANTLER Phase 1 trial at dose level 1: 6/6 patients (100%) achieved CR, 3/6 (50%) maintained CR at 6 months.","Designations offer expedited development benefits: Priority Review, Rolling Review, Accelerated Approval eligibility."],"urls":{"canonical":"https://secwatch.observer/filing/0001619856-22-000029","json":"https://secwatch.observer/filing/0001619856-22-000029.json","markdown":"https://secwatch.observer/filing/0001619856-22-000029.md","text":"https://secwatch.observer/filing/0001619856-22-000029.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1619856/000161985622000029/0001619856-22-000029-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1619856/000161985622000029/crbu-20221129.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-21T12:17:39.619368+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}